Equities

EvokAI Creative Labs Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
OKAI:CVE

EvokAI Creative Labs Inc

Actions
Health CareHealth Care Providers
  • Price (CAD)0.115
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-23.33%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EvokAI Creative Labs Inc. is a MedTech artificial-intelligence-powered company. It is engaged in the development of transformational technologies for the modern healthcare sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. It tailors its artificial intelligence (AI) algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals, aiming at preventing any kind of disease and, beyond, protecting the aging genome. The Company has a single operating segment, which is involved in the research and development and commercialization of artificial intelligence-based products and services for the MedTech sector.

  • Revenue in CAD (TTM)-12.90k
  • Net income in CAD-13.53m
  • Incorporated2017
  • Employees--
  • Location
    EvokAI Creative Labs Inc1600-609 Granville StreetPacific CentrePO Box 10068VANCOUVER V7Y 1C3CanadaCAN
  • Phone+1 (778) 331-8505
  • Fax+1 (778) 508-9923
  • Websitehttps://www.evokailabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evome Medical Technologies Inc48.34m-23.53m298.12k195.00------0.0062-0.2867-0.28670.556-0.04150.93852.996.57247,908.80-45.69---161.45--33.80---48.68--0.2409-1.841.24--------------
Imaging Dynamics Co Ltd104.20k-1.07m460.81k23.00------4.42-0.1033-0.10330.0101-0.55250.56031.9522.58---573.96-200.65----65.0461.63-1,024.48-444.170.0054-0.6348-----39.16-37.85-44.96---29.84--
EvokAI Creative Labs Inc-12.90k-13.53m866.64k-----------1.92-1.92-0.0017-0.1741-0.0019-------194.40-1,742.96-206.27-3,585.36-----------69.67---------3,392.77------
CardioComm Solutions Inc386.53k-404.82k1.96m16.00------5.06-0.0021-0.00210.002-0.00291.311.482.97---137.51-20.56----87.2583.20-104.73-9.130.2344-11.998.47---39.90-9.65-99.92---10.07--
Therma Bright Inc75.23k-4.16m3.10m--------41.15-0.0729-0.07290.0013-0.02480.04060.17260.3653---224.22-203.01-69,250.66-507.5765.25---5,523.12-9,158.610.1182-0.6815----207.9084.25-77.17------
Zero Candida Technologies Inc-100.00bn-100.00bn3.40m----2.09----------0.0839----------------------------0.0174--------------
Data as of May 08 2025. Currency figures normalised to EvokAI Creative Labs Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.